GSK256066是一种选择性的PDE4B(与A-D亚型具有相等的亲和力)抑制剂，IC50为3.2 pM，比作用于PDE1/2/3/5/6选择性高380，000倍以上，作用于PDE4B比作用于PDE7选择性高2500倍以上。GSK256066 是缓慢但紧密结合的PDE4B抑制剂，IC50为3.2 pM。GSK256066作用于PBMCs，强有效抑制LPS刺激的TNFα产生，pIC50 为11.0，IC50 为10 pM，GSK256066作用于人全血培养物，pIC50为9.90，IC50为 126 pM。GSK256066高选择性抑制 PDE4(是抑制PDE1,PDE2, PDE3, PDE5, 和PDE6的3.8×10⁵多倍，是抑制PDE7的2.5×10³多倍)。

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO ：5 mg/mL (9.64 mM)

PDE4B

GSK256066 is a slow and tight binding inhibitor of PDE4B with apparent IC50 of 3.2 pM. GSK256066 is an extremely potent inhibitor of LPS-stimulated TNFα production in PBMCs with pIC50 of 11.0 and IC50 of 10 pM and human whole-blood cultures with pIC50 of 9.90 and IC50 of 126 pM. GSK256066 is highly selective for PDE4 (>3.8 × 105-fold versus PDE1, PDE2, PDE3, PDE5, and PDE6 and >2.5 × 103-fold against PDE7). GSK256066 inhibits PDE4 isoforms A-D with equal affinity.

GSK256066 inhibits the LPS-induced pulmonary neutrophilia with an ED50 of 1.1 μg/kg, achieving maximal inhibition of 72% at 30 μg/kg when given in the aqueous suspension. GSK256066 inhibits the LPS-induced pulmonary neutrophilia with ED50 of 2.9 μg/kg, achieving maximal inhibition of 62% when given in the dry powder formulation. GSK256066 shows a moderate plasma clearance of 39 ml/min/kg, a moderate volume of distribution of 0.8 L/kg, and a relatively short half-life of 1.1 hour in the male CD rat. GSK256066 sustains at a high lung concentration of 2.6 μg/g after intra-tracheal administration as an aqueous suspension at a dose of 30 μg/kg in rats. GSK256066 (10 μg/kg) is administered intratracheally at different times (2, 6, 12, 18, 24, and 36 hours) before LPS administration, inhibiting LPS-Induced Pulmonary Neutrophilia in rat lipopolysaccharide (LPS)-induced models of acute pulmonary inflammation. GSK256066 (0.3–100 μg/kg) inhibits LPS-induced increases in exhaled nitric oxide with ED50 of 35 μg/kg in rat. GSK256066 (10 μg/kg) is administered half a hour before OVA administration in rat, inhibiting OVA-induced pulmonary eosinophilia with ED50 of 0.4 μg/kg. GSK256066 administered intratracheally as a dry powder blended in respiratory-grade lactose at doses of 3 to 100 μg/kg 2 hours before inhaled LPS challenge in ferrets, inhibiting LPS-induced pulmonary neutrophilia with ED50 of 18 μg/kg without inducing emetic episodes.

In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
Nialset al. J Pharmacol Exp Ther. 2011 Apr;337(1):137-44. PMID: 21䔸Żᩄ族痛셌Ų族痛셌ŲItem褐Count๏
﯈趌๐侮᠜׶靴๟
ᠠ׶iS￿￿ññ眘⮦眀⮦敲痛๏
ࠃ馸๟鳘๟௼଩祖ItemǓǘ„Count洣盜᬴叫㺍痭ᠠ׶靴๟i縉靴๟蘿敌ଧ靴๟ᠠ׶i᭰叫㺍痭ᡸ׶顴๟਋먲ନ魈๟鸤๟�ଭ鶔๟׶懲랖ନܬ煮ﭬz�ଭ鶔๟삲W鸤๟ᨼĊ煮섈W豈勤섫W豈཰́煮ﭬz
섪W섲W཰́褐ﭔzᇈMoveEof„Ǔǘꯍ�혐珂„劬盜蠊똉Ⴚ啑盜ᦤ叫㺍痭ᠠ׶靴๟i侮﯈褐靴๟婢敌ଧ靴๟ᠠ׶i靴๟䢸Ş䢸Ş⌅痜Ѐ￾￿￾￿ꁠ๒⌅痜
Ѐ䢸Ş￾￿쿹࡜痮Љ
䕄Ż顴๟蘿ॡ痮 ᤀ
ꋔŻ
蘿ᩄᡴ׶冨๘瑉浥ᛨ׶擄୔ᡴ׶冨๘潃湵tw௪讻Q௪④Q„௪劬盜躂똉Ⴚ啑盜勐盜�✰혐珂Ⴚ뼠Ǖ
Ȁ Àז梕盜
Ǔǘ„ 曀盞$䢸Ş戀䢸Ş輦⌅痜⌅痜穀Ѐ￾￿￾￿ꁠ๒
䢸Ş